Type I Interferon Therapy for Hard-to-Target Brachyury Cancers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Brachyury-associated cancers, such as chordoma, are difficult to treat due to the transcription factor's difficulty in targeting and the lack of effective targeted molecular therapeutics, leading to poor prognosis outcomes.

Innovation Solution

Administering a therapeutically effective amount of type I interferon, such as interferon alpha or interferon beta, to subjects with brachyury-associated cancers, either systemically or through intratumoral or subcutaneous administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If targeted molecular therapeutics are developed for brachyury-associated cancers, then treatment effectiveness is improved, but the complexity of identifying and targeting the transcription factor brachyury increases the difficulty of treatment development

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtargeting complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses interferon as an intermediary substance that indirectly targets brachyury-associated cancers. Instead of directly targeting the brachyury transcription factor (which is difficult due to its nuclear location and function), interferon acts as a mediator that triggers immune responses and cellular mechanisms that selectively eliminate cancer cells expressing brachyury, thereby resolving the targeting complexity issue while maintaining treatment effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic approach from direct molecular targeting to using interferon-induced cellular and immune parameter changes. By administering interferon, the treatment exploits changes in cellular proliferation, differentiation, and immune recognition parameters that are dysregulated in brachyury-associated cancers, achieving effective treatment without the complexity of direct transcription factor targeting

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional therapies are used for brachyury-associated cancers, then treatment simplicity is maintained, but prognosis outcomes remain poor

Engineering Contradiction:

Improveprognosis outcomeVSAvoidtreatment simplicity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs interferon's self-service property where the substance automatically triggers multiple therapeutic mechanisms including immune activation, cellular differentiation, and anti-proliferation effects. This self-service mechanism improves prognosis outcomes without requiring complex treatment protocols or additional therapeutic agents, thereby maintaining treatment simplicity while enhancing effectiveness

Inventive Principle:

Principle #25Self-service

3Reliability

If direct targeting of brachyury is attempted, then treatment specificity is improved, but off-target effects increase due to the transcription factor's essential roles in development

Engineering Contradiction:

Improvetreatment specificityVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Interferon serves as a selective intermediary that targets cancer cells expressing brachyury through indirect mechanisms. The treatment specificity is achieved through interferon-induced changes in cellular markers and immune recognition that are specific to brachyury-associated cancers, while avoiding direct interference with brachyury's essential developmental functions, thereby minimizing off-target effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the potential harm of brachyury's essential developmental role into a benefit by using interferon to selectively target only the aberrant brachyury expression in cancer cells. The interferon treatment exploits the dysregulated brachyury pathway in tumors while leaving normal developmental processes unaffected, transforming the potential harm of targeted intervention into a beneficial selective treatment

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250288648A1Interferon for the treatment of brachyury-associated cancers and neoplasms

Publication Date: 2025.09.18 THE GENERAL HOSPITAL CORP

AI summary

Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.